Persistent ENT Manifestations in Individuals who Recovered from COVID-19: A Systematic Review

Abstract

Introduction Long coronavirus disease (COVID) refers to the persistence of symptoms long after the recovery from the acute phase of the illness, and it is due to the interplay of various inflammatory mechanisms. This has led to emergence of new deficits, including otorhinolaryngological symptoms, in patients wo have recovered from COVID. The plethora of otorhinolaryngological symptoms associated with long COVID are tinnitus, sensorineural hearing loss (SNHL), vertigo, nasal congestion, sinonasal discomfort, hyposmia/anosmia, dysgeusia, sore throat, dry cough, dyspnea, dysphagia, and hoarseness of voice.

Objective To evaluate the possible ENT symptoms in patients wo have recovered from COVID and to combine those findings with our experience.

Data Synthesis We conducted a search on the PubMed, ENT Cochrane, Web of Science, and Google Scholar databases, and a total of 44 studies were selected for the present review.

Conclusion Otorhinolaryngological complications such as tinnitus, SNHL, vertigo, nasal congestion, sinonasal discomfort, hyposmia/anosmia, dysgeusia, sore throat, dry cough, dyspnea, dysphagia, and hoarseness of voice have been widely reported among in long-COVID patients.

Keywords

long COVID - SARS-CoV-2 - otorhinolaryngological manifestations

Introduction

In December 2019, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) originated in Wuhan, China.[1] On March 11, 2020, due to its unprecedented global spread, the World Health Organization (WHO) labelled coronavirus disease 2019 (COVID-19), the infection caused by SARS-CoV-2, a pandemic.[2] It is a very aggressive and contagious illness that spreads mostly by aerosols and respiratory droplets.[3] The primary entry points for the virus are the nasal and oral cavities, with the nasal cavity and nasopharynx being the most common sites for viral replication. The virus binds to the angiotensin-converting enzyme 2 (ACE2) receptor and initiates an inflammatory cascade with multisystem involvement.[4] [5] [6] The symptoms may range from minor ailments to life-threatening complications. In addition to symptoms of the lower respiratory tract, such as cough, fever, and dyspnea, extrapulmonary symptoms affecting the ear, nose, and throat are also often observed.[7]

It has been observed that most SARS-CoV-2-positive patients did not require any hospitalization and presented with mild or no symptoms. Among these mild symptoms, alterations in the senses of smell and taste have been observed to occur early. [8]

While some of the symptoms diminish with time, others have catastrophic long-term effects that persist even after recovery from the acute infection, resulting in death or significant impairment of functions. “Long COVID” or “post-COVID syndrome” refers to this unusual and unexpected persistence of symptoms long after recovery from the initial illness.[9] Long COVID is associated with a plethora of otorhinolaryngological symptoms, including tinnitus, sensorineural hearing loss (SNHL), vertigo, nasal congestion, sinonasal discomfort, hyposmia/anosmia, dysgeusia, sore throat, dry cough, dyspnea, dysphagia, and hoarseness of voice.

Materials and Methods

We conducted a search on the PubMed, ENT Cochrane, Web of Science, and Google Scholar databases without restrictions regarding the time of publication of the articles, with an emphasis on the most recent reports, using the terms COVID-19, long COVID, and otorhinolaryngological manifestation or ENT symptoms. Boolean operators (AND, NOT, and OR) were used to restrict and extend the search. Long COVID can refer to certain symptoms that seem to persist (from three to nine months or longer) in an individual who has recovered from COVID-19.[10] However, some authors [11] also believe these symptoms can persist for years.

Initially, 462 articles were retrieved based on our search parameters. Out of these, 392 publications were excluded, as they were not found to be relevant to the topic in question. Consequently, a total of 70 studies were selected for the present review. The purpose of the current article is to compile the broad spectrum of ear, nose, and throat (ENT) presentations of long COVID and to highlight the diagnosis based on the available literature combined with our experience.

Review of the Literature

Otological Symptoms after COVID-19

We analyzed 25 articles in detail to highlight the symptoms and treatment of the otological symptoms of long COVID exclusively. Combined, the data from these studies revealed that out of 1,000 patients who have recovered from COVID, 80 (8%) presented with SNHL, 140 (14%), with tinnitus, 142 (14.2%), with vertigo, 2 (0.2%), with facial paralysis, 19 (1.9%), with an earache, and 58 (5.81%) presented with aural fullness. The broad spectrum of ear symptoms after recovery from COVID are hearing loss, tinnitus, vertigo, facial palsy, earache, and aural fullness.[12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36]

At our center, approximately 22 patients reported to us with symptoms of hearing loss, tinnitus and aural fullness; 4 out of them presented with tinnitus along with hearing loss, 14, with hearing loss without any other symptoms, and 4, with aural fullness. These patients are still being treated and are under follow-up.

Nasal and Associated Chemosensory Deficit Symptoms Following COVID-19

We analyzed 11 studies in detail to conclude that the most common nasal and associated chemosensory deficit symptoms are smell and taste dysfunctions, such as phantosmia, parosmia, hyposmia, anosmia, phantogeusia, parageusia, ageusia, or rhinitis symptoms, such as nasal discharge, nasal blockage, and sinonasal pain.[33] [34] [36] [37] [38] [39] [40] [41] [42] [43]

In each study, the authors observed chemosensory deficit symptoms, including dysfunctions in the senses of smell and taste in 861 patients (31.22%) out of a total of 2,757 patients who have recovered from COVID. Six[33] [34] [37] [40] [41] [43] out of 10 studies identified rhinitis symptoms in 385 (19.63%) of a total 1,961 patients.

In 2022, Bianco et al. [44] conducted a prospective study on 76 patients for an objective assessment of olfactory function, which revealed that 48 (63.16%) patients had recovered completely, 26 (34.21%) were hyposmic, and 2 (2.63%) were anosmic. The authors reported [44] that the duration of the SARS-CoV-2 infection was observed to be more severe among individuals who did not regain their sense of smell. Hence, they could safely conclude that the duration of the infection negatively correlates with the recovery of olfactory function.

A total of four patients presented to the ENT Outpatient Department (OPD) at our center with nasal complications of long COVID. While 3 out of 4 patients reported with hyposmia, 1 presented with complaints of anosmia. These patients are still under follow up.

Throat and Laryngeal Symptoms after COVID-19

A total of 10 studies were taken into consideration in order to ascertain that the most prevalent throat and laryngeal symptoms include hoarseness of voice, sore throat, dry throat, trouble swallowing, dyspnea, and cough.[34] [36] [39] [43] [45] [46] [47] [48] [49]

Out of the 1,826 subjects who have recovered from COVID included in these studies, symptoms of hoarseness of voice were observed in 110 patients (6.02%), sore throat, in 214 (11.72%), dry throat, in 26 (1.42%), difficulty in swallowing in 33 (1.81%), dyspnea, in 313 (17.14%), and cough, in 344 patients (18.84%).

In 4 out of 10 studies,[45] [46] [48] [49] the authors also reported history of intubation, accounting for 52 of 207 (25.12%) patients who had recovered from COVID.

At our center, we have only observed one patient with a finding of vocal cord paresis. We have not observed any other laryngeal complications of long COVID.

Discussion

The infection by SARS-CoV-2 (COVID-19) is a highly contagious illness with catastrophic effects, which has caused great mortality and morbidity on a global scale. About 80% of the afflicted patients presented with mild to moderate disease, whereas 5% of the cases were considered critical.[50] Long COVID or post-COVID refers to the persistence of many symptoms weeks or months after the infection by SARS-CoV-2, regardless of the viral state.[51] Long-term COVID may be ongoing or have a relapsing, remitting nature.[52] There may be a continuation of one or more acute COVID symptoms, or the emergence of new symptoms. Most individuals with post-COVID syndrome are polymerase chain reaction (PCR) negative, which indicates recovery of the virus. The lag between microbiological and clinical recovery is referred to as post-COVID syndrome.[53] Most long-term COVID patients recover biochemically and radiologically.[54]

Long COVID may be caused by the persistence of inflammatory process or immune response/autoantibody production, the persistence of the virus in the body, the sequelae of organ dysfunction, and the varying time involved for the regeneration of each organ, postintensive care syndrome, complications due to the COVID infection or complications due to underlying diseases or adverse effects of the medications used. Therefore, multiple pathways contribute to the development of long COVID in various patients.[55] [56] Long COVID patients commonly experience extreme fatigue, shortness of breath, cough, chest discomfort, palpitations, headache, joint pain, muscle ache and fatigue, insomnia, diarrhea, poor balance and gait, neurocognitive disorders such as memory and attention problems, and a decline in quality of life.[57]

Tinnitus, SNHL, vertigo, facial paralysis, earache, aural fullness, gustatory and olfactory dysfunctions, rhinitis symptoms such as nasal discharge and nasal obstruction, dyspnea, cough, hoarseness of voice, dysphagia, sore throat, and dry throat are otorhinolaryngological symptoms of long COVID. based on these symptoms, neuro-otorhinolaryngological symptoms can be explained through various mechanisms. This might be due to hypoxia caused by respiratory failure, immune-mediated injury, coagulation problems, or direct viral invasion.[58]

The SARS-Cov-2 virus can also cause direct damage by binding to the ACE2 receptor, which is commonly expressed in the nasal, laryngeal, or tracheal tracts, as well as in the neuro-olfactory epithelium, the lungs, the Eustachian tube, the middle ear, the cochlear hair cells, the oral cavity, including the taste buds, the endothelium of blood vessels, and the thyroid gland. This virus may directly infiltrate tissue and, since it is neuroinvasive and neurotrophic, it can cause axonal transport, thus causing long-term damage to individual neurons. Involvement of the nasal, laryngeal, and tracheal tracts, as well as the neuro-olfactory epithelium, results in rhinitis, anosmia, sore throat, dry throat, dysphagia, hoarseness of voice, and cough. Involvement of the lungs results in dyspnea, hypoxic symptoms, and hemoptysis.

Involvement of the Eustachian tube and middle ear causes earache and aural fullness. The combination of cochlear hair cells with the involvement of the vestibulocochlear nerve and facial nerve results in cochlear neuritis/labrynthitis or vestibular neuritis, hence further adding to the symptoms of SNHL, tinnitus, vertigo, and facial nerve paralysis. Involvement of the oral cavity, including the taste buds, results in gustatory impairment. Due to the predilection of the virus for the thyroid gland through the ACE 2 receptors, thyroid involvement results in subacute thyroiditis.[59] [60] [61] [62]

Involvement of terminal cochlear artery supply resulting in SNHL and tinnitus, as a result of indirect ischemia injury, is another possible cause of audiovestibular symptoms. There is degradation of the basal lamina of endothelial cells, congestion of blood vessels, and an infiltration of macrophages, astrocytes, and lymphocytes around the blood vessels. This also causes microhemorrhages in the parenchyma and labyrinth of the brain.[17] [19] [63] There is an aberrant immune response characterized by the formation of a significant number of autoantibodies directed against blood vessels, which may lead to autoimmune thrombocytopenia and the subsequent development of labyrinthine ischemia due to hypoxia.[64] [65]

In the etiopathogenesis of neuro-otorhinolaryngological symptoms, inflammatory cytokines and their overproduction also play a role. Their excessive production is the cause of chronic symptoms. Interleukin 6 generated by the lymphocytes, the fibroblasts, and the bronchial epithelium during SARS-CoV-2 infection may control synaptic plasticity, alter cerebral blood flow, and induce neuroinflammation.[66] [67]

In addition to the aforementioned processes, the use of ototoxic medicines such as hydroxychloroquine, favipiravir, azithromycin, and furosemide to treat COVID might result in reversible or irreversible hearing impairment.[68] [69] [70] [71]

In our opinion, the treatment for the otorhinolaryngological symptoms of long-term COVID requires a multidisciplinary strategy that includes examination, symptomatic therapy, treatment of underlying issues, and long-term monitoring of ongoing symptoms for the identification and timely intervention regarding the complications.

Monitored steroids at a low dose can be used for the treatment of the inflammatory processes such as neuroinflammation. However, steroids must be administered with caution and after taking complete medical history of the patient in detail. The uncontrolled and injudicious use of steroids is has also been observed to result in sequelae like mucormycosis in long-COVID patients.

Final Comments

Numerous complications of long COVID have been reported in the literature, with ENT complications contributing greatly to the impact on the lives of patients after the pandemic. We have observed that otorhinolaryngological complications, such as tinnitus, SNHL, vertigo, nasal congestion, sinonasal discomfort, hyposmia/anosmia, dysgeusia, sore throat, dry cough, dyspnea, dysphagia, hoarseness of voice, and hypothyroidism have been widely reported. We believe that although “wait and watch” is the immediate answer to any mild complaint, steroids and nootropic medicines might play some role in the treatment of certain complications mentioned in the present review. However, a detailed medical history and adequate dosage and duration of medication use are the mainstay of the management of most ENT complications of long COVID.

Conflict of Interests

The authors have no conflict of interest to declare.

• References

• 1 El-Anwar MW, Elzayat S, Fouad YA. ENT manifestation in COVID-19 patients. Auris Nasus Larynx 2020; 47 (04) 559-564
• 2 Guan WJ, Ni ZY, Hu Y. et al; China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382 (18) 1708-1720
• 3 Heller L, Mota CR, Greco DB. COVID-19 faecal-oral transmission: Are we asking the right questions?. Sci Total Environ 2020; 729: 138919
• 4 Gengler I, Wang JC, Speth MM, Sedaghat AR. Sinonasal pathophysiology of SARS-CoV-2 and COVID-19: A systematic review of the current evidence. Laryngoscope Investig Otolaryngol 2020; 5 (03) 354-359
• 5 Hoffmann M, Kleine-Weber H, Schroeder S. et al. SARS-CoV-2 Cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020; 181 (02) 271-280.e8
• 6 Hussman JP. Cellular and molecular pathways of COVID-19 and potential points of therapeutic intervention. Front Pharmacol 2020; 11: 1169
• 7 Tuang GJ, Abdul Wahab AF, Husain S. Otolaryngology manifestations of COVID-19: a contemporary viewpoint. Postgrad Med J 2022; 98 (e2): e97-e98
• 8 Bianco MR, Modica DM, Drago GD. et al. Alteration of smell and taste in asymptomatic and symptomatic COVID-19 patients in sicily, italy. Ear Nose Throat J 2021; 100 (2_suppl, suppl) 182S-185S
• 9 National Institute for Health and Care Excellence. COVID-19 rapid guideline: managing the long-term effects of COVID-19 NICE guideline. ; c 2020 https://www.nice.org.uk/guidance/ng188
• 10 https://www.who.int/podcasts/series/science-in-5/episode–47−post-covid-19-condition
• 11 Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol 2023; 21 (03) 133-146
• 12 Kilic O, Kalcioglu MT, Cag Y. et al. Could sudden sensorineural hearing loss be the sole manifestation of COVID-19? An investigation into SARS-COV-2 in the etiology of sudden sensorineural hearing loss. Int J Infect Dis 2020; 97: 208-211
• 13 Degen C, Lenarz T, Willenborg K. Acute Profound Sensorineural Hearing Loss After COVID-19 Pneumonia. Mayo Clin Proc 2020; 95 (08) 1801-1803
• 14 Abdel Rhman S, Abdel Wahid A. COVID -19 and sudden sensorineural hearing loss, a case report. Otolaryngol Case Rep 2020; 16: 100198
• 15 Lang B, Hintze J, Conlon B. Coronavirus disease 2019 and sudden sensorineural hearing loss. J Laryngol Otol 2020; 134: 1-3
• 16 Koumpa FS, Forde CT, Manjaly JG. Sudden irreversible hearing loss post COVID-19. BMJ Case Rep 2020; 13 (11) e238419
• 17 Lamounier P, Franco Gonçalves V, Ramos HVL. et al. A 67-Year-Old Woman with Sudden Hearing Loss Associated with SARS-CoV-2 Infection. Am J Case Rep 2020; 21: e927519
• 18 Karimi-Galougahi M, Naeini AS, Raad N, Mikaniki N, Ghorbani J. Vertigo and hearing loss during the COVID-19 pandemic - is there an association?. Acta Otorhinolaryngol Ital 2020; 40 (06) 463-465
• 19 Chern A, Famuyide AO, Moonis G, Lalwani AK. Bilateral Sudden Sensorineural Hearing Loss and Intralabyrinthine Hemorrhage in a Patient With COVID-19. Otol Neurotol 2021; 42 (01) e10-e14
• 20 Aasfara J, Hajjij A, Bensouda H, Ouhabi H, Benariba F. A unique association of bifacial weakness, paresthesia and vestibulocochlear neuritis as post-COVID-19 manifestation in pregnant women: a case report. Pan Afr Med J 2021; 38: 30
• 21 Beckers E, Chouvel P, Cassetto V, Mustin V. Sudden sensorineural hearing loss in COVID-19: A case report and literature review. Clin Case Rep 2021; 9 (04) 2300-2304
• 22 Edwards M, Muzaffar J, Naik P, Coulson C. Catastrophic bilateral sudden sensorineural hearing loss following COVID-19. BMJ Case Rep 2021; 14 (06) e243157
• 23 Ozer F, Alkan O. Simultaneous Sudden Hearing Loss and Peripheral Facial Paralysis in a Patient with COVID-19. Ear Nose Throat 2021
• 24 Ricciardiello F, Pisani D, Viola P. et al. Sudden Sensorineural Hearing Loss in Mild COVID-19: Case Series and Analysis of the Literature. Audiology Res 2021; 11 (03) 313-326
• 25 Gerstacker K, Speck I, Riemann S, Aschendorff A, Knopf A, Arndt S. Deafness after COVID-19?. HNO 2021; 69 (Suppl. 02) 92-95
• 26 Jeong M, Ocwieja KE, Han D. et al. Direct SARS-CoV-2 infection of the human inner ear may underlie COVID-19-associated audiovestibular dysfunction. Commun Med (Lond) 2021; 1 (01) 44
• 27 Pokharel S, Tamang S, Pokharel S, Mahaseth RK. Sudden sensorineural hearing loss in a post-COVID-19 patient. Clin Case Rep 2021; 9 (10) e04956
• 28 Asfour L, Kay-Rivest E, Roland Jr JT. Cochlear implantation for single-sided deafness after COVID-19 hospitalization. Cochlear Implants Int 2021; 22 (06) 353-357
• 29 Raymaekers V, D'hulst S, Herijgers D. et al. Susac syndrome complicating a SARS-CoV-2 infection. J Neurovirol 2021; 27 (06) 954-959
• 30 Viola P, Ralli M, Pisani D. et al. Tinnitus and equilibrium disorders in COVID-19 patients: preliminary results. Eur Arch Otorhinolaryngol 2021; 278 (10) 3725-3730
• 31 Bhatta S, Sharma S, Sharma D. et al. Study of hearing status in COVID-19 patients: a multicentered review. Indian J Otolaryngol Head Neck Surg 2021; 1-7
• 32 Gallus R, Melis A, Rizzo D. et al. Audiovestibular symptoms and sequelae in COVID-19 patients. J Vestib Res 2021; 31 (05) 381-387
• 33 Kökoğlu K, Tektaş N, Baktir-Okcesiz FEM, Şahin Mİ. Mild and moderate COVID-19 disease does not affect hearing function permanently: a cross-sectional study ınvolving young and middle-aged healthcare givers. Eur Arch Otorhinolaryngol 2021; 278 (09) 3299-3305
• 34 Thrane JF, Britze A, Fjaeldstad AW. Incidence and duration of self-reported hearing loss and tinnitus in a cohort of COVID-19 patients with sudden chemosensory loss: a STROBE observational study. Eur Ann Otorhinolaryngol Head Neck Dis 2021:S1879-7296(21)00224-6
• 35 Gedik Ö, Hüsam H, Başöz M, Tas N, Aksoy F. The effect of coronavirus disease 2019 on the hearing system. J Laryngol Otol 2021; 135 (09) 810-814
• 36 Graham EL, Clark JR, Orban ZS. et al. Persistent neurologic symptoms and cognitive dysfunction in non-hospitalized Covid-19 “long haulers”. Ann Clin Transl Neurol 2021; 8 (05) 1073-1085
• 37 Boscolo-Rizzo P, Guida F, Polesel J. et al. Sequelae in adults at 12 months after mild-to-moderate coronavirus disease 2019 (COVID-19). Int Forum Allergy Rhinol 2021; 11 (12) 1685-1688
• 38 Havervall S, Rosell A, Phillipson M. et al. Symptoms and Functional Impairment Assessed 8 Months After Mild COVID-19 Among Health Care Workers. JAMA 2021; 325 (19) 2015-2016
• 39 Augustin M, Schommers P, Stecher M. et al. Post-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort study. Lancet Reg Health Eur 2021; 6: 100122
• 40 Vaira LA, Gessa C, Deiana G. et al. The Effects of Persistent Olfactory and Gustatory Dysfunctions on Quality of Life in Long-COVID-19 Patients. Life (Basel) 2022; 12 (02) 141
• 41 Carvalho-Schneider C, Laurent E, Lemaignen A. et al. Follow-up of adults with noncritical COVID-19 two months after symptom onset. Clin Microbiol Infect 2021; 27 (02) 258-263
• 42 Ercoli T, Masala C, Pinna I. et al. Qualitative smell/taste disorders as sequelae of acute COVID-19. Neurol Sci 2021; 42 (12) 4921-4926
• 43 Lackermair K, Wilhelm K, William F. et al. The prevalence of persistent symptoms after COVID-19 disease. Dtsch Arztebl Int 2022; 119 (10) 175-176
• 44 Bianco MR, Ralli M, Minni A, Greco A, de Vincentiis M, Allegra E. Evaluation of olfactory dysfunction persistence after COVID-19: a prospective study. Eur Rev Med Pharmacol Sci 2022; 26 (03) 1042-1048
• 45 Halpin SJ, McIvor C, Whyatt G. et al. Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: A cross-sectional evaluation. J Med Virol 2021; 93 (02) 1013-1022
• 46 El Kik A, Eid H, Aoun Bacha Z. Post-COVID-19 paradoxical vocal cord movement and dysfunctional dysphonia: A clinical case. Respir Med Case Rep 2022; 39: 101710
• 47 Dassie-Leite AP, Gueths TP, Ribeiro VV, Pereira EC, Martins PDN, Daniel CR. Vocal Signs and Symptoms Related to COVID-19 and Risk Factors for their Persistence. J Voice 2021; :S0892-1997 (21) 00253-8
• 48 Neevel AJ, Smith JD, Morrison RJ, Hogikyan ND, Kupfer RA, Stein AP. Postacute COVID-19 Laryngeal Injury and Dysfunction. OTO Open 2021; 5 (03) X211041040
• 49 Kang YR, Oh JY, Lee JH, Small PM, Chung KF, Song WJ. Long-COVID severe refractory cough: discussion of a case with 6-week longitudinal cough characterization. Asia Pac Allergy 2022; 12 (02) e19
• 50 Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020; 323 (13) 1239-1242
• 51 Geddes L. Why strange and debilitating coronavirus symptoms can last for months. New Sci 2020 https://www.newscientist.com/article/mg24632881-400-why-strange-and-debilitatingcoronavirus-symptoms-can-last-for-months/
• 52 Nabavi N. Long covid: How to define it and how to manage it. BMJ 2020; 370: m3489
• 53 Garg P, Arora U, Kumar A, Wig N. The “post-COVID” syndrome: how deep is the damage?. J Med Virol 2020
• 54 Greenhalgh T, Knight M, A'Court C, Buxton M, Husain L. Management of post-acute covid-19 in primary care. BMJ 2020; 370: m3026
• 55 Colafrancesco S, Alessandri C, Conti F, Priori R. COVID-19 gone bad: A new character in the spectrum of the hyperferritinemic syndrome?. Autoimmun Rev 2020; 19 (07) 102573
• 56 Tay MZ, Poh CM, Rénia L, MacAry PA, Ng LFP. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol 2020; 20 (06) 363-374
• 57 Raveendran AV, Jayadevan R, Sashidharan S. Long COVID: An overview. Diabetes Metab Syndr 2021; 15 (03) 869-875
• 58 Fancello V, Hatzopoulos S, Corazzi V. et al. SARS-CoV-2 (COVID-19) and audio-vestibular disorders. Int J Immunopathol Pharmacol 2021;35:20587384211027373
• 59 De Luca P, Di Stadio A, Colacurcio V. et al. Long COVID, audiovestibular symptoms and persistent chemosensory dysfunction: a systematic review of the current evidence. Acta Otorhinolaryngol Ital 2022; 42 (2, Suppl. 1) S87-S93
• 60 Fancello V, Fancello G, Hatzopoulos S. et al. Sensorineural Hearing Loss Post-COVID-19 Infection: An Update. Audiology Res 2022; 12 (03) 307-315
• 61 Safwan M, Vijayan KN, Najeeb, Jithu TG. Post-Coronavirus Disease 2019 De Quervain's Thyroiditis – A Case Report and Literature Review. Innovare Journal of Medical Sciences 2021; 9 (02) 4-6
• 62 Muller I, Cannavaro D, Dazzi D. et al. SARS-CoV-2-related atypical thyroiditis. Lancet Diabetes Endocrinol 2020; 8 (09) 739-741
• 63 Lee M-H, Perl DP, Nair G. et al. Microvascular Injury in the Brains of Patients with Covid-19. N Engl J Med 2021; 384 (05) 481-483
• 64 Angileri F, Legare S, Marino Gammazza A, Conway de Macario E, Jl Macario A, Cappello F. Molecular mimicry may explain multi-organ damage in COVID-19. Autoimmun Rev 2020; 19 (08) 102591
• 65 Kaliyappan K, Chen YC, Krishnan Muthaiah VP. Vestibular Cochlear Manifestations in COVID-19 Cases. Front Neurol 2022; 13: 850337
• 66 Gruol DL. IL-6 regulation of synaptic function in the CNS. Neuropharmacology 2015; 96 (Pt A): 42-54
• 67 De Luca P, Scarpa A, Ralli M. et al. Auditory disturbances and SARS-CoV-2 infection: brain inflammation or cochlear affection? Systematic review and discussion of potential pathogenesis. Front Neurol 2021; 12: 707207
• 68 Johansen PB, Gran JT. Ototoxicity due to hydroxychloroquine: report of two cases. Clin Exp Rheumatol 1998; 16 (04) 472-474
• 69 Cianfrone G, Pentangelo D, Cianfrone F. et al. Pharmacological drugs inducing ototoxicity, vestibular symptoms and tinnitus: a reasoned and updated guide. Eur Rev Med Pharmacol Sci 2011; 15 (06) 601-636
• 70 Elfiky AA. Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study. Life Sci 2020; 253: 117592
• 71 Ciorba A, Corazzi V, Skarżyński PH. et al. Don't forget ototoxicity during the SARS-CoV-2 (Covid-19) pandemic!. Int J Immunopathol Pharmacol 2020;34:2058738420941754

Publication History

Received: 18 May 2023

Accepted: 12 November 2023

Article published online:
15 March 2024